Welcome to our dedicated page for Sigyn Therapeutics news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on Sigyn Therapeutics stock.
Sigyn Therapeutics, Inc. (SIGY) is a development-stage medical technology company whose news flow centers on its dialysis-like blood purification therapies and related corporate developments. Company announcements highlight progress on Sigyn Therapy, a novel blood purification technology aimed at pathogen-associated inflammatory disorders, as well as its oncology-focused platforms ImmunePrep, ChemoPrep, and ChemoPure.
News releases frequently cover clinical and regulatory milestones, such as plans for first-in-human feasibility studies of Sigyn Therapy in end-stage renal disease patients with endotoxemia and concurrent inflammation, drafting of an Investigational Device Exemption for submission to the U.S. Food and Drug Administration, and discussions of potential Breakthrough Device submissions. Investors can also find updates on annual and quarterly financial results, including the filing of Form 10-K and other SEC reports referenced in company communications.
Sigyn Therapeutics also issues news about capital markets and corporate actions, including its 1-for-40 reverse stock split and efforts to meet listing requirements for The Nasdaq Capital Market. Coverage includes participation in emerging growth and small-cap conferences, such as the Emerging Growth Conference and LD Micro Main Event, where management presents updates on the companys therapeutic pipeline and development plans.
In addition, third-party research coverage, such as reports from Goldman Small Cap Research, is sometimes summarized in press releases that describe Sigyn Therapeutics as a developer of next-generation blood purification therapies for life-threatening conditions without FDA-approved treatments. For investors and observers, the SIGY news feed offers a consolidated view of clinical planning, technology development, financing steps, and investor outreach activities related to the companys blood purification and oncology-support platforms.
Sigyn Therapeutics, Inc. (OTC Markets: SIGY) has appointed Dr. Alexander S. Yevzlin to its Scientific Advisory Board. Dr. Yevzlin, a leader in Interventional Nephrology, brings extensive experience from his academic and clinical background to advance Sigyn Therapy, a blood purification technology targeting life-threatening inflammatory disorders, including sepsis. His contributions are expected to aid in the clinical advancement of this innovative therapy. Sigyn Therapy aims to address various critical conditions, enhancing the company's focus on significant health challenges.
Sigyn Therapeutics, Inc. (OTC Markets: SIGY) announced the appointment of Jeremy Ferrell, CPA, MBA, as its new Chief Financial Officer, effective March 9, 2022. With over 25 years of finance and operations leadership experience, Ferrell aims to enhance operational finance and manage investor relations. Previously CFO at Miku, Inc., he has notable experience in the life sciences sector. CEO Jim Joyce expressed confidence in Ferrell's ability to support the advancement of Sigyn Therapy and the pursuit of a major exchange listing, highlighting the importance of his role during this transformative period.
Sigyn Therapeutics announced the successful completion of an in vivo animal study, demonstrating that Sigyn Therapy is safe and well tolerated during six-hour treatments. This novel blood purification technology targets life-threatening inflammatory conditions like sepsis. The study involved administering therapy to eight porcine subjects with stable health parameters and no serious adverse events. The company plans to submit data for an Investigational Device Exemption to the FDA, aiming for human clinical studies.
Sigyn Therapeutics (OTC Markets: SIGY) announced that its CEO, Jim Joyce, will present at the Bullseye Small Cap Virtual Investor Conference on January 27, 2022, at 3:30 PM Eastern. The presentation will focus on Sigyn Therapy™, a blood purification technology aimed at treating pathogen-related conditions leading to sepsis, a major cause of hospital fatalities. Attendees can register for the event and schedule one-on-one meetings with company management for further discussions.
Sigyn Therapeutics, Inc. (OTC: SIGY) announced that Chairman and CEO Jim Joyce will present at the virtual Emerging Growth Conference on January 5, 2022, at 3:30 PM Eastern Time. The conference connects publicly traded companies with investors and focuses on growth sectors. Sigyn Therapeutics is dedicated to treating pathogen-related conditions causing sepsis, which is the leading cause of hospital deaths globally. The company's Sigyn Therapy employs a dual-function blood purification technology to extract harmful pathogens and inflammatory mediators from the bloodstream.
Sigyn Therapeutics (OTC: SIGY) has progressed its Sigyn Therapy, aimed at treating sepsis, with significant milestones achieved in 2021. The company completed five in vitro blood purification studies demonstrating the therapy’s ability to address various pathogens, including COVID-19. Manufacturing enhancements allow greater efficiency, enabling up to seven bloodstream passes during treatment. A pilot animal study has been successfully completed, paving the way for potential human trials in 2022. The company is preparing an Investigational Device Exemption (IDE) for FDA submission to initiate these studies.
Sigyn Therapeutics, Inc. (OTC: SIGY), a medical technology company, is advancing its Sigyn Therapy, a dual-function blood purification system aimed at treating pathogen-related conditions, particularly in the context of sepsis. This technology targets a variety of viral pathogens and inflammatory mediators, including COVID-19. The company highlights the importance of blood purification devices in addressing severe infections, especially as pandemic threats continue. Sigyn Therapy is designed for use with existing hospital equipment, and aims to broaden its applications beyond infectious diseases.
Sigyn Therapeutics, Inc. (OTC: SIGY) announced promising preclinical results for its Sigyn Therapy, a dual-function blood purification technology. The therapy demonstrated the ability to significantly reduce gram-positive bacterial toxins in human blood plasma, crucial in treating sepsis—a leading cause of hospital deaths. With reductions of ~50% for peptidoglycan and ~70% for lipoteichoic acid within two hours, the results support the technology's potential. Sigyn Therapy targets a range of pathogen-associated illnesses, including drug-resistant infections and community-acquired pneumonia.
Sigyn Therapeutics, Inc. (OTC Markets: SIGY) announced an interview with CEO Jim Joyce on Tech Nation, discussing their innovative Sigyn Therapy. This therapy aims to treat life-threatening inflammatory conditions caused by cytokine storm syndrome, a critical issue during the COVID-19 pandemic. Joyce highlighted the device's dual function: eliminating inflammatory cytokines and targeting their sources, like viral pathogens. The potential market opportunity exceeds $20 billion, positioning Sigyn Therapy as pivotal in addressing severe health concerns.
Sigyn Therapeutics (OTC Markets: SIGY) announced its continued development of Sigyn Therapy, aimed at treating sepsis and inflammatory conditions. The therapy exhibits capabilities to target a broad range of inflammatory agents, including viral pathogens and cytokines. The technology features over 170,000 square meters of surface area for adsorption, significantly more than its competitors. The company is preparing an Investigational Device Exemption (IDE) to initiate human clinical studies, building on positive results from prior animal studies. The potential market exceeds $20 billion.